Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Completes Deal for $35M Investment, New CEO Named

NEW YORK (GenomeWeb News) – Accelr8 today announced that it has received shareholder approval, met all closing conditions, and completed a transaction that will bring in a $35 million investment.

The investment, which was announced in April, will go toward the development and commercialization of the company's BACcel culture-free diagnostic system for same-shift identification and antibiotic resistance testing of bacterial and fungal pathogens.

The investment was led by Jack Schuler, John Patience, and Lawrence Mehren, who were all appointed to Accelr8's board. Mehren also was named CEO of Accelr8, succeeding Tom Geimer.

Schuler and Patience are principals and founders of Crabtree Partners. Mehren was most recently head of global business of Roche Tissue Diagnostics. Before that, he was CFO of Ventana Medical Systems, a Roche business.

In Wednesday afternoon trading on the New York Stock Exchange, shares of Accelr8 were down 5 percent at $2.60.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.